Monoclonal Antibodies
Rituximab + Cyclosporine for Glomerulonephritis
Recruiting1 awardPhase 2
Bethesda, Maryland
This trial is testing the safety and effectiveness of combining two drugs to treat membranous nephropathy, a kidney disease associated with damage to the walls of the glomeruli. The first drug, rituximab, is an immunosuppressant that attempts to reduce the activity of the immune system. The second drug, cyclosporine, is a blood pressure lowering medication. The trial will last up to 2 years, and participants will have frequent blood and urine tests.
Alkylating agents
Cord Blood Transplant + Chemo/Radiation for Leukemia and Lymphoma
Recruiting1 awardPhase 2
Aurora, Colorado
This trial is testing whether giving an umbilical cord blood transplant together with chemotherapy and radiation therapy works better than just giving an umbilical cord blood transplant for treating patients with hematologic disease.
Alkylating agents
Combination Chemotherapy + Cyclosporine and Focal Therapy for Retinoblastoma
Recruiting1 awardPhase 2
Vancouver, British Columbia
This trial is studying a combination of chemotherapy drugs with or without cyclosporine followed by cryotherapy (freezing) and/or laser therapy in treating patients with newly diagnosed retinoblastoma in both eyes.
Popular Filters
Phase 3 Trials
Immunosuppressant
L-CsA + Standard of Care for Bronchiolitis Obliterans Syndrome
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial is testing how safe and effective L-CsA plus Standard of Care is in treating Breathing Obstruction Syndrome in people who have had either a single or double lung transplant.
Immunomodulator
Etanercept vs Cyclosporine for Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
Recruiting1 awardPhase 3
Nashville, Tennessee
This trial is testing whether two therapeutic interventions (etanercept vs cyclosporine) are better than supportive care alone for treating Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
Trials With No Placebo
MEK Inhibitor
Selumetinib + Cyclosporine for Colorectal Cancer
Recruiting1 awardPhase 1
Sacramento, California
This trial studies the combination of Selumetinib and Cyclosporine in patients with advanced cancers that do not respond to standard treatments. Selumetinib blocks growth signals in cancer cells, while Cyclosporine helps by modifying the immune system. Cyclosporine is an immunosuppressive drug that has been used in human transplants and autoimmune diseases, and it has been approved for use in dermatology for many years.
Alkylating agents
Cord Blood Transplant for Leukemia
Recruiting3 awards4 criteria
Minneapolis, Minnesota
This trial is testing a new way to treat leukemia with an unrelated umbilical cord blood transplant. The transplant will use a myeloablative preparative regimen, which will include the drugs cyclophosphamide, fludarabine, and fractionated total body irradiation.
Immunosuppressant
Bone Marrow Transplant for Dyskeratosis Congenita
Recruiting3 awardsPhase 2
Los Angeles, California
This trial tests a new bone marrow transplant method for patients with Dyskeratosis congenita. It uses fludarabine and antibodies to avoid harmful side effects, aiming to improve survival and reduce complications. Fludarabine-based regimens have been shown to be effective and feasible in reducing transplant-related morbidity in patients with Dyskeratosis congenita.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.